Compare Ishares Msci Spain ETF (EWP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Ishares Msci Spain ETF trades at $57.72 (market cap $2.30B), while Vertex Pharmaceuticals Incorporated trades at $509.67 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 55.5× Ishares Msci Spain ETF's market cap, and Ishares Msci Spain ETF is more actively traded (845,747 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 40 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EWP | VRTX | |
|---|---|---|
Market Cap | $2.30B | $127.55B |
Volume | 845,747 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $557.96 |
52-Week Low | $48.33 | $407.37 |
Typical Hold Time | 40 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
